Centurion Shores Up Biotech Outfit With $10M Investment

Law360, New York (October 13, 2011, 6:54 PM EDT) -- Centurion Private Equity LLC is banking on pioneering biotechnology from Amarantus BioSciences Inc., investing $10 million to help the startup develop treatments for Parkinson’s and other diseases, Amarantus announced Thursday.

Centurion is taking a stake in Amarantus as it works to develop therapies based on a protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor. MANF is a disease-modifying protein that corrects apoptosis, or cell death, that characterizes Parkinson’s and ischemic heart disease, the biotech company said in a statement.

“Centurion is pleased to partner with Amarantus to unlock...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.